Cargando…

Effects of Neddylation and mTOR Inhibition in Acute Myelogenous Leukemia

Acute myelogenous leukemia (AML) is a heterogeneous disease and often relapses after standard chemotherapy. Recently, the neddylation (NEDD8) and the mammalian target of rapamycin (mTOR) signaling pathways have emerged as promising pharmaceutical targets for AML therapy. However, the interaction of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Naxin, Azadniv, Mitra, Coppage, Myra, Nemer, Mary, Mendler, Jason, Becker, Michael, Liesveld, Jane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2019
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348338/ https://www.ncbi.nlm.nih.gov/pubmed/30699367 http://dx.doi.org/10.1016/j.tranon.2019.01.001

Ejemplares similares

Bone marrow mesenchymal stromal cells from acute myelogenous leukemia patients demonstrate adipogenic differentiation propensity with implications for leukemia cell support
por: Azadniv, Mitra, et al.
Publicado: (2019)

Targeting Myelogenous Leukemia Stem Cells: Role of the Circulation
por: Liesveld, Jane
Publicado: (2012)

Hydroxycitric Acid Inhibits Chronic Myelogenous Leukemia Growth through Activation of AMPK and mTOR Pathway
por: Verrelli, Doriana, et al.
Publicado: (2022)

Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia
por: Lai, Qiu-yu, et al.
Publicado: (2019)

Inhibition of neddylation regulates dendritic cell functions via Deptor accumulation driven mTOR inactivation
por: Cheng, Mengmeng, et al.
Publicado: (2016)

Correction: Inhibition of neddylation regulates dendritic cell functions via Deptor accumulation driven mTOR inactivation
por: Cheng, Mengmeng, et al.
Publicado: (2018)

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
por: Martelli, Alberto M., et al.
Publicado: (2010)

Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis
por: Serrano-Maciá, Marina, et al.
Publicado: (2021)

Biological Aspects of mTOR in Leukemia
por: Mirabilii, Simone, et al.
Publicado: (2018)

Cytotoxicity of Algae Extracts on Normal and Malignant Cells
por: Bechelli, Jeremy, et al.
Publicado: (2011)

Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway
por: Li, Jie, et al.
Publicado: (2019)

Targeting mTOR in Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2019)

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines
por: Xin, Pengliang, et al.
Publicado: (2017)

AAA + ATPase Thorase inhibits mTOR signaling through the disassembly of the mTOR complex 1
por: Umanah, George K. E., et al.
Publicado: (2022)

Camptothecin Inhibits Neddylation to Activate the Protective Autophagy Through NF-κB/AMPK/mTOR/ULK1 Axis in Human Esophageal Cancer Cells
por: Heng, Yongqing, et al.
Publicado: (2021)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
por: Fransecky, Lars, et al.
Publicado: (2015)

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
por: Evangelisti, Camilla, et al.
Publicado: (2018)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

mTOR and lysosome regulation
por: Puertollano, Rosa
Publicado: (2014)

mTOR, autophagy, and reprogramming
por: Tang, Bor Luen
Publicado: (2014)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

mTOR in cerebrovascular disease
por: Van Skike, Candice E., et al.
Publicado: (2019)

mTOR and Tumor Cachexia
por: Duval, Adrian P., et al.
Publicado: (2018)

Double agent mTOR
por: Danzer, Steve C.
Publicado: (2019)

mTOR in Human Diseases
por: Dormond, Olivier
Publicado: (2019)

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition
por: Mitchell, Rebecca, et al.
Publicado: (2017)

Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)

How mRNA is misspliced in acute myelogenous leukemia (AML)?
por: Mohamed, Aminetou Mint, et al.
Publicado: (2014)

Chronic myelogenous leukemia in Libya
por: Mehdi, Itrat, et al.
Publicado: (2012)

Chronic myelogenous leukemia on target
por: Némethová, Veronika, et al.
Publicado: (2018)

Activated mTOR signaling pathway in myofibers with inherited metabolic defect might be an evidence for mTOR inhibition therapies
por: Lyu, Jing-Wei, et al.
Publicado: (2019)

mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging
por: Węsierska-Gądek, Józefa
Publicado: (2010)

Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders
por: Gipson, Tanjala T., et al.
Publicado: (2012)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8mresn3lfeu2mtebn4nk2a53oq